Our portfolio

Jeito Capital is building a strong and diversified portfolio in Biopharma and innovative medical companies.

Neogene Therapeutics

Oncology - Cell Therapy
Acquired by AstraZenecaFinalised in January 2023 Round of $110 millionSeptember 2020

Sparing Vision

Ophtalmology - Gene Therapy
Rounds of:€44,5 million – September 2020€75 million – Septembre 2022

innoSkel

Rare bone Diseases - Gene Therapy
Round of €20 millionDecember 2020

Pulmocide

Inhaled Respiratory Medicine
Rounds of: $92 million - May 2021$52 million - December 2022

Alentis Therapeutics

Fibrotic Diseases Medicine
Rounds of:CHF60 million - June 2021€96 million - April 2023

Quell Therapeutics

T-reg cell therapy in auto-immune and inflammatory diseases
Round of $156 millionNovember 2021

NMD Pharma

Severe neuromuscular diseases
Rounds of:€35 million - February 2022€75 million - November 2023

EyeBio

Eye disease therapies
Rounds of:$65 million - February 2022$65 million - November 2023

Precirix

Oncology therapies
Round of €80 millionMarch 2022

CDR-Life

Immuno-oncology therapies
Round of $76 millionApril 2022

HI-Bio

Auto-Immune Diseases - Antibody
Round of $120 millionNovember 2022

CatalYm

Immuno-Oncology Therapies
Round of €50 millionNovember 2022

Noema Pharma

DEBILITATING CENTRAL NERVOUS SYSTEM DISORDERS
Round of €104 millionMarch 2023

Corteria Pharmaceuticals

CARDIOVASCULAR DISEASES
Round of €65 millionSeptember 2023

At a glance

key data

investments in portfolio

millions euros under management

In short

Discover Jeito news

Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.